Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of preventive cardiology"
DOI: 10.1093/eurjpc/zwac315
Abstract: AIMS To assess treatment eligibility for, and received treatment with, sodium-glucose co-transporter 2 inhibitors (SGLT2) and glucagon-like peptide-1 (GLP-1) receptor agonists according to the 2019 ADA/EASD consensus report and the 2019 ESC guidelines in a… read more here.
Keywords: receptor agonists; according 2019; 2019 esc; esc guidelines ... See more keywords